Recently, the National High-tech Enterprise Certification and Management Work Network published the "Public Announcement on the Filing of the First Batch of High-Tech Enterprises Certified and Filed in Shenzhen City for 2025" .Shenzhen Cell Valley Biomedical Co., Ltd. (hereinafter referred to as "Shenzhen Cell Valley") successfully passed the National High-Tech Enterprise recognition and has officially joined the ranks of National High-Tech Enterprises.

Shenzhen Cell Valley was established in November 2021, focusing on core technology research and development, industrial transformation, and one-stop CRO/CDMO services in the field of Cell and Gene Therapy (CGT). In the four years since its establishment, the company has adhered to the core driving force of original technology and engineering capabilities. In the three years since its official production launch, it has continuously increased R&D investment, constructing a comprehensive technical system covering stem cell and immune cell preparation, viral/virus-like vectors, gene delivery systems, and quality control, forming scalable, replicable, and regulated industrialization capabilities.

The National High-Tech Enterprise recognition is a comprehensive uation of an enterprise's independent intellectual property rights, technological achievement transformation capabilities, R&D organization and management level, and sustained innovation capabilities. This successful passage of the recognition fully demonstrates that Shenzhen Cell Valley has received national-level authoritative recognition for its key foundational technologies in cell and gene therapy, industrialization platform construction, and technological innovation system.

As a cell and gene therapy platform enterprise based in Shenzhen, facing the country and expanding into the international market, Shenzhen Cell Valley will take this High-Tech Enterprise recognition as a new starting point. It will continue to deepen core technological breakthroughs, accelerate the transformation of scientific research achievements into clinical and industrial applications, and actively participate in the construction of the biomedical industry ecosystem in the country and the Guangdong-Hong Kong-Macao Greater Bay Area, contributing greater strength to promoting the high-quality development of China's cell and gene therapy industry.